Annual CFI
$77.54 M
+$302.73 M+134.43%
December 31, 2023
Summary
- As of February 20, 2025, PCRX annual cash flow from investing activities is $77.54 million, with the most recent change of +$302.73 million (+134.43%) on December 31, 2023.
- During the last 3 years, PCRX annual CFI has risen by +$355.15 million (+127.93%).
- PCRX annual CFI is now at all-time high.
Performance
PCRX Cash From Investing Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly CFI
-$52.16 M
-$36.95 M-242.84%
September 30, 2024
Summary
- As of February 20, 2025, PCRX quarterly cash flow from investing activities is -$52.16 million, with the most recent change of -$36.95 million (-242.84%) on September 30, 2024.
- Over the past year, PCRX quarterly CFI has dropped by -$47.82 million (-1101.36%).
- PCRX quarterly CFI is now -155.22% below its all-time high of $94.46 million, reached on September 30, 2018.
Performance
PCRX Quarterly CFI Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
TTM CFI
-$74.53 M
-$47.82 M-179.02%
September 30, 2024
Summary
- As of February 20, 2025, PCRX TTM cash flow from investing activities is -$74.53 million, with the most recent change of -$47.82 million (-179.02%) on September 30, 2024.
- Over the past year, PCRX TTM CFI has dropped by -$154.89 million (-192.75%).
- PCRX TTM CFI is now -148.89% below its all-time high of $152.44 million, reached on September 30, 2018.
Performance
PCRX TTM CFI Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Cash From Investing Formula
CFI = Cash Inflows from Investments − Cash Outflows for Investments
PCRX Cash From Investing Trends
PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
---|---|---|---|
1 y1 year | +134.4% | -1101.4% | -192.8% |
3 y3 years | +127.9% | +74.9% | +57.0% |
5 y5 years | +276.9% | +74.9% | +57.0% |
PCRX Cash From Investing Highs & Lows
PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
---|---|---|---|---|---|---|---|
3 y | 3-year | at high | +134.4% | -177.9% | +74.9% | -192.8% | +66.9% |
5 y | 5-year | at high | +127.9% | -177.9% | +74.9% | -192.8% | +77.9% |
alltime | all time | at high | +127.9% | -155.2% | +74.9% | -148.9% | +77.9% |
Pacira BioSciences Cash From Investing History
Date | Annual | Quarterly | TTM |
---|---|---|---|
Sep 2024 | - | -$52.16 M(+242.8%) | -$74.53 M(+179.0%) |
Jun 2024 | - | -$15.21 M(-2.0%) | -$26.71 M(+540.3%) |
Mar 2024 | - | -$15.53 M(-285.5%) | -$4.17 M(-105.4%) |
Dec 2023 | $77.54 M(-134.4%) | $8.37 M(-292.9%) | $77.54 M(-3.5%) |
Sep 2023 | - | -$4.34 M(-159.3%) | $80.36 M(+116.1%) |
Jun 2023 | - | $7.33 M(-88.9%) | $37.18 M(-24.1%) |
Mar 2023 | - | $66.18 M(+491.5%) | $49.02 M(-121.8%) |
Dec 2022 | -$225.19 M(+983.1%) | $11.19 M(-123.5%) | -$225.19 M(+32.9%) |
Sep 2022 | - | -$47.52 M(-348.0%) | -$169.46 M(+7.9%) |
Jun 2022 | - | $19.16 M(-109.2%) | -$157.02 M(-9.3%) |
Mar 2022 | - | -$208.02 M(-410.9%) | -$173.15 M(+732.8%) |
Dec 2021 | -$20.79 M(-92.5%) | $66.92 M(-290.8%) | -$20.79 M(-87.8%) |
Sep 2021 | - | -$35.08 M(-1256.5%) | -$170.03 M(-49.7%) |
Jun 2021 | - | $3.03 M(-105.4%) | -$337.80 M(+10.9%) |
Mar 2021 | - | -$55.66 M(-32.4%) | -$304.70 M(+9.8%) |
Dec 2020 | -$277.61 M(+116.1%) | -$82.32 M(-59.4%) | -$277.61 M(+22.8%) |
Sep 2020 | - | -$202.85 M(-661.5%) | -$226.09 M(+1183.6%) |
Jun 2020 | - | $36.12 M(-226.5%) | -$17.61 M(-92.5%) |
Mar 2020 | - | -$28.57 M(-7.2%) | -$235.53 M(+83.3%) |
Dec 2019 | -$128.49 M(-724.5%) | -$30.80 M(-647.5%) | -$128.49 M(-41.8%) |
Sep 2019 | - | $5.63 M(-103.1%) | -$220.86 M(+67.3%) |
Jun 2019 | - | -$181.80 M(-331.6%) | -$132.02 M(-220.7%) |
Mar 2019 | - | $78.48 M(-163.7%) | $109.35 M(+431.4%) |
Dec 2018 | $20.58 M(-109.2%) | -$123.16 M(-230.4%) | $20.58 M(-86.5%) |
Sep 2018 | - | $94.46 M(+58.6%) | $152.44 M(+399.8%) |
Jun 2018 | - | $59.57 M(-678.8%) | $30.50 M(-133.8%) |
Mar 2018 | - | -$10.29 M(-218.3%) | -$90.22 M(-59.7%) |
Dec 2017 | -$223.76 M | $8.70 M(-131.7%) | -$223.76 M(-6.5%) |
Sep 2017 | - | -$27.48 M(-55.1%) | -$239.38 M(+6.3%) |
Jun 2017 | - | -$61.15 M(-57.5%) | -$225.22 M(+22.6%) |
Date | Annual | Quarterly | TTM |
---|---|---|---|
Mar 2017 | - | -$143.84 M(+1979.5%) | -$183.72 M(+197.5%) |
Dec 2016 | -$61.75 M(+220.7%) | -$6.92 M(-48.1%) | -$61.75 M(+29.9%) |
Sep 2016 | - | -$13.32 M(-32.2%) | -$47.54 M(+10.7%) |
Jun 2016 | - | -$19.64 M(-10.2%) | -$42.96 M(+3.9%) |
Mar 2016 | - | -$21.88 M(-399.8%) | -$41.33 M(+114.6%) |
Dec 2015 | -$19.26 M(-84.0%) | $7.30 M(-183.5%) | -$19.26 M(-20.6%) |
Sep 2015 | - | -$8.74 M(-51.5%) | -$24.25 M(-79.2%) |
Jun 2015 | - | -$18.01 M(-9105.0%) | -$116.69 M(-9.7%) |
Mar 2015 | - | $200.00 K(-91.3%) | -$129.25 M(+7.3%) |
Dec 2014 | -$120.43 M(+180.5%) | $2.31 M(-102.3%) | -$120.43 M(+12.0%) |
Sep 2014 | - | -$101.19 M(+231.0%) | -$107.52 M(+3854.4%) |
Jun 2014 | - | -$30.57 M(-439.0%) | -$2.72 M(-112.2%) |
Mar 2014 | - | $9.02 M(-40.7%) | $22.33 M(-152.0%) |
Dec 2013 | -$42.94 M(+45.4%) | $15.22 M(+321.1%) | -$42.94 M(+19.9%) |
Sep 2013 | - | $3.62 M(-165.5%) | -$35.80 M(-13.2%) |
Jun 2013 | - | -$5.52 M(-90.2%) | -$41.22 M(-50.5%) |
Mar 2013 | - | -$56.25 M(-351.6%) | -$83.24 M(+182.0%) |
Dec 2012 | -$29.52 M(-18.3%) | $22.36 M(-1336.0%) | -$29.52 M(-53.6%) |
Sep 2012 | - | -$1.81 M(-96.2%) | -$63.65 M(-1.2%) |
Jun 2012 | - | -$47.54 M(+1779.1%) | -$64.41 M(+70.3%) |
Mar 2012 | - | -$2.53 M(-78.5%) | -$37.82 M(+4.7%) |
Dec 2011 | -$36.12 M(+433.7%) | -$11.77 M(+358.8%) | -$36.12 M(+32.3%) |
Sep 2011 | - | -$2.56 M(-87.8%) | -$27.30 M(+2.5%) |
Jun 2011 | - | -$20.96 M(+2419.0%) | -$26.64 M(+270.8%) |
Mar 2011 | - | -$832.00 K(-71.8%) | -$7.18 M(+6.1%) |
Dec 2010 | -$6.77 M(+22.9%) | -$2.95 M(+55.3%) | -$6.77 M(+77.2%) |
Sep 2010 | - | -$1.90 M(+26.0%) | -$3.82 M(+98.7%) |
Jun 2010 | - | -$1.51 M(+261.2%) | -$1.92 M(+361.2%) |
Mar 2010 | - | -$417.00 K | -$417.00 K |
Dec 2009 | -$5.51 M(-5.6%) | - | - |
Dec 2008 | -$5.84 M | - | - |
FAQ
- What is Pacira BioSciences annual cash flow from investing activities?
- What is the all time high annual CFI for Pacira BioSciences?
- What is Pacira BioSciences annual CFI year-on-year change?
- What is Pacira BioSciences quarterly cash flow from investing activities?
- What is the all time high quarterly CFI for Pacira BioSciences?
- What is Pacira BioSciences quarterly CFI year-on-year change?
- What is Pacira BioSciences TTM cash flow from investing activities?
- What is the all time high TTM CFI for Pacira BioSciences?
- What is Pacira BioSciences TTM CFI year-on-year change?
What is Pacira BioSciences annual cash flow from investing activities?
The current annual CFI of PCRX is $77.54 M
What is the all time high annual CFI for Pacira BioSciences?
Pacira BioSciences all-time high annual cash flow from investing activities is $77.54 M
What is Pacira BioSciences annual CFI year-on-year change?
Over the past year, PCRX annual cash flow from investing activities has changed by +$302.73 M (+134.43%)
What is Pacira BioSciences quarterly cash flow from investing activities?
The current quarterly CFI of PCRX is -$52.16 M
What is the all time high quarterly CFI for Pacira BioSciences?
Pacira BioSciences all-time high quarterly cash flow from investing activities is $94.46 M
What is Pacira BioSciences quarterly CFI year-on-year change?
Over the past year, PCRX quarterly cash flow from investing activities has changed by -$47.82 M (-1101.36%)
What is Pacira BioSciences TTM cash flow from investing activities?
The current TTM CFI of PCRX is -$74.53 M
What is the all time high TTM CFI for Pacira BioSciences?
Pacira BioSciences all-time high TTM cash flow from investing activities is $152.44 M
What is Pacira BioSciences TTM CFI year-on-year change?
Over the past year, PCRX TTM cash flow from investing activities has changed by -$154.89 M (-192.75%)